Nonlinear Appoints International Sales Manager
News Nov 29, 2005
Nonlinear Dynamics Ltd has announced that it has appointed Martin Wells as International Sales Manager. The appointment marks the latest development in Nonlinear’s strategic development of its EU markets.
A Biochemistry graduate, Martin joins Nonlinear from Helena BioSciences where he worked for 13 years.
During this time, he held a variety of senior sales and marketing positions in their Life Sciences and Clinical In Vitro Diagnostics division, specialising in clinical electrophoresis and haematology.
In his new capacity with Nonlinear, Martin will be responsible for the management of group sales activities throughout Europe including telesales and direct sales channels.
The role also includes the provision of both remote and on-the-ground support to sales personnel on location.
John Spreadbury, Group Sales and Marketing Director at Nonlinear Dynamics and CEO of Nonlinear USA Inc., said, "The development of our direct sales channels continues to be of key strategic significance for the company."
"Martin is an excellent addition to Nonlinear bringing with him a great degree of knowledge both as a manager and as a sales specialist. We are very much looking forward to his impact in this role."
Martin Wells added, "Nonlinear operates with a very ambitious business ethic, to continually deliver better products, better services and better value for the customer."
"Following the successful launch of the company’s revised product range in the summer, there are many exciting developments in motion, and it is great to be involved."
"I am looking forward to the challenges of this new role in growing our market presence throughout Europe, and in bringing scientists the very latest developments in proteomics analysis innovation."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.